Abstract
BRAF V600E is a constitutive BRAF (B-raf proto-oncogene, serine/threonine kinase) mutation that accounts for more than 90% of BRAF mutations in melanoma. Vemurafenib is a BRAF V600E selective kinase inhibitor (BRAFi) that is commonly used to treat BRAF V600E melanoma patients. However, vemurafenib treatment-induced resistance occurs in about 50% of patients diagnosed with melanoma, and half of the patients have disease progression within six months. But the mechanism and the consequences of BRAF inhibitor resistance have not been fully elucidated. In this review, we summarize the mechanism and the consequences of BRAF inhibitor vemurafenib resistance in melanoma, aiming to provide a guidance for the intervention of BRAF inhibitor resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Acciardo, S., Mignion, L., Joudiou, N., Bouzin, C., Baurain, J. F., Gallez, B., & Jordan, B. F. (2018). Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas. Oncotarget, 9(24), 16832–16846.
Arozarena, I., & Wellbrock, C. (2017). Overcoming resistance to BRAF inhibitors. Ann Transl Med, 5(19), 387.
Ascierto, P.A., Kirkwood, J.M., Grob, J.J., Simeone, E., Grimaldi, A.M., Maio, M., Palmieri, G., Testori, A., Marincola, F.M., & Mozzillo, N. (2012). The role of BRAF V600 mutation in melanoma. J Transl Med 10 85. https://doi.org/10.1186/1479-5876-10-85
Atefi, M., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J. A., Comin-Anduix, B., et al. (2011). Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE, 6(12), e28973.
Becker, T. M., Boyd, S. C., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G. M., Scolyer, R. A., Mann, G. J., Kefford, R. F., Zhang, X. D., et al. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158–1166.
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature, 463(7283), 899–905.
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews. Drug Discovery, 11(11), 873–886.
Booth, L., Roberts, J. L., Sander, C., Lee, J., Kirkwood, J. M., Poklepovic, A., & Dent, P. (2017). The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget, 8(10), 16367–16386.
Chan, X. Y., Singh, A., Osman, N., & Piva, T. J. (2017). Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. International Journal of Molecular Sciences, 18(7), 1527. https://doi.org/10.3390/ijms18071527
Cseh, B., Doma, E., & Baccarini, M. (2014). “RAF” neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Letters, 588(15), 2398–2406. https://doi.org/10.1016/j.febslet.2014.06.025
Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., & Sarkar, F. H. (2008). Evolving role of uPA/uPAR system in human cancers. Cancer Treatment Reviews, 34(2), 122–136. https://doi.org/10.1016/j.ctrv.2007.10.005
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949–954. https://doi.org/10.1038/nature00766
Dummer, R., & Flaherty, K.T. (2012). Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 24(2) 150–154. https://doi.org/10.1097/CCO.0b013e32834fca92
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019). HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. Cancer Research, 79(11), 2947–2961. https://doi.org/10.1158/0008-5472.Can-19-0040
Fecher, L. A., Amaravadi, R. K., & Flaherty, K. T. (2008). The MAPK pathway in melanoma. Current Opinion in Oncology, 20(2), 183–189. https://doi.org/10.1097/CCO.0b013e3282f5271c
Flaherty, K. T., Hodi, F. S., & Fisher, D. E. (2012). From genes to drugs: targeted strategies for melanoma. Nature Reviews Cancer, 12(5), 349–361. https://doi.org/10.1038/nrc3218
Garbe, C., & Eigentler, T. K. (2018). Vemurafenib. Recent Results in Cancer Research, 211, 77–89. https://doi.org/10.1007/978-3-319-91442-8_6
Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., et al. (2013). Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 3(2) 158–167. https://doi.org/10.1158/2159-8290.Cd-12-0386
Goding, C. R., & Arnheiter, H. (2019). MITF-the first 25 years. Genes & Development, 33(15–16), 983–1007. https://doi.org/10.1101/gad.324657.119
Hernandez-Davies, J. E., Tran, T. Q., Reid, M. A., Rosales, K. R., Lowman, X. H., Pan, M., Moriceau, G., Yang, Y., Wu, J., Lo, R. S., et al. (2015). Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. Journal of Translational Medicine, 13, 210. https://doi.org/10.1186/s12967-015-0581-2
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014). Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nature Reviews Cancer, 14(7), 455–467. https://doi.org/10.1038/nrc3760
Ishimura, N., Yamasawa, K., Karim Rumi, M. A., Kadowaki, Y., Ishihara, S., Amano, Y., Nio, Y., Higami, T., & Kinoshita, Y. (2003). BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Letters, 199(2), 169–173. https://doi.org/10.1016/s0304-3835(03)00384-7
Jing, N., & Tweardy, D. J. (2005). Targeting Stat3 in cancer therapy. Anti-Cancer Drugs, 16(6), 601–607. https://doi.org/10.1097/00001813-200507000-00002
JitianMihulecea, C. R., & Rotaru, M. (2023). Review: The Key Factors to Melanomagenesis. Life (basel), 13(1), 181. https://doi.org/10.3390/life13010181
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326), 968–972. https://doi.org/10.1038/nature09627
KaramiFath, M., Azargoonjahromi, A., Soofi, A., Almasi, F., Hosseinzadeh, S., Khalili, S., Sheikhi, K., Ferdousmakan, S., Owrangi, S., Fahimi, M., et al. (2022). Current understanding of epigenetics role in melanoma treatment and resistance. Cancer Cell International, 22(1), 313. https://doi.org/10.1186/s12935-022-02738-0
Knight, T., & Irving, J. A. (2014). Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Frontiers in Oncology, 4, 160. https://doi.org/10.3389/fonc.2014.00160
Kontomanolis, E. N., Koutras, A., Syllaios, A., Schizas, D., Mastoraki, A., Garmpis, N., Diakosavvas, M., Angelou, K., Tsatsaris, G., Pagkalos, A., et al. (2020). Role of oncogenes and tumor-suppressor genes in carcinogenesis a review. Anticancer Research, 40(11), 6009–6015.
Kotmayer, L., Romero-Moya, D., Marin-Bejar, O., Kozyra, E., Català, A., Bigas, A., Wlodarski, M. W., Bödör, C., & Giorgetti, A. (2022). GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects. British Journal of Haematology, 199(4), 482–495. https://doi.org/10.1111/bjh.18330
Lehraiki, A., Cerezo, M., Rouaud, F., Abbe, P., Allegra, M., Kluza, J., Marchetti, P., Imbert, V., Cheli, Y., Bertolotto, C., et al. (2015). Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib. Cell Discov. https://doi.org/10.1038/celldisc.2015.30
Lesinski, G. B. (2013). The potential for targeting the STAT3 pathway as a novel therapy for melanoma. Future Oncology, 9(7), 925–927. https://doi.org/10.2217/fon.13.83
Lipsick, J. (2022). A History of Cancer Research: Retroviral Oncogenes. Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a035865
Liu, F., Cao, J., Wu, J., Sullivan, K., Shen, J., Ryu, B., Xu, Z., Wei, W., & Cui, R. (2013). Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. The Journal of Investigative Dermatology, 133(8), 2041–2049. https://doi.org/10.1038/jid.2013.32
Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Journal of Clinical Oncology, 29(10), 1239–1246. https://doi.org/10.1200/jco.2010.32.4327
Luebker, S. A., & Koepsell, S. A. (2019). Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies. Frontiers in Oncology, 9, 268. https://doi.org/10.3389/fonc.2019.00268
Luo, H., Umebayashi, M., Doi, K., Morisaki, T., Shirasawa, S., & Tsunoda, T. (2016). Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells. Anticancer Research, 36(7), 3585–3589.
MadorskyRowdo, F. P., Barón, A., Gallagher, S. J., Hersey, P., Emran, A. A., Von Euw, E. M., Barrio, M. M., & Mordoh, J. (2020). Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition. International Journal of Oncology, 56(6), 1429–1441. https://doi.org/10.3892/ijo.2020.5031
Manzano, J. L., Layos, L., Bugés, C., & de Los Llanos Gil, M., Vila, L., Martínez-Balibrea, E., & Martínez-Cardús, A. (2016). Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med, 4(12), 237.
Menzies, A. M., & Long, G. V. (2014). Systemic treatment for BRAF-mutant melanoma: where do we go next? The Lancet Oncology, 15(9), e371-381. https://doi.org/10.1016/s1470-2045(14)70072-5
Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Zweegman, S., Caillon, H., Caillot, D., et al. (2021). The Lancet Oncology, 22(10), 1378–1390. https://doi.org/10.1016/s1470-2045(21)00428-9
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D., GeukesFoppen, M. H., et al. (2014). Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nature Communications, 5, 5712. https://doi.org/10.1038/ncomms6712
Musi, A., & Bongiovanni, L. (2023). Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy. Cancers (basel). https://doi.org/10.3390/cancers15041074
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002). Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene, 21(46), 7001–7010. https://doi.org/10.1038/sj.onc.1205859
NwaboKamdje, A. H., Seke Etet, P. F., Vecchio, L., Tagne, R. S., Amvene, J. M., Muller, J. M., Krampera, M., & Lukong, K. E. (2014). New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers. World J Clin Cases, 2(12), 769–786.
Paraiso, K. H., Das Thakur, M., Fang, B., Koomen, J. M., Fedorenko, I. V., John, J. K., Tsao, H., Flaherty, K. T., Sondak, V. K., Messina, J. L., et al. (2015). Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discovery, 5(3), 264–273. https://doi.org/10.1158/2159-8290.Cd-14-0293
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M. D., & Corre, S. (2022). The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma. EMBO Molecular Medicine, 14(12), e15677.
Peng, Z., Gillissen, B., Richter, A., Sinnberg, T., Schlaak, M. S., & Eberle, J. (2023). Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins. International Journal of Molecular Sciences, 24(5), 4961. https://doi.org/10.3390/ijms24054961
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022). Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clinical Cancer Research, 28(21), 4618–4628. https://doi.org/10.1158/1078-0432.Ccr-21-2138
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018). Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell, 174(4), 843–855. https://doi.org/10.1016/j.cell.2018.06.025
Reddi, K. K., Guruvaiah, P., Edwards, Y. J. K., & Gupta, R. (2022). Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells. Frontiers in Oncology, 12, 937831.
Saenz-Santamaría, M. C., Reed, J. A., McNutt, N. S., & Shea, C. R. (1994). Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. Journal of Cutaneous Pathology, 21(5), 393–397. https://doi.org/10.1111/j.1600-0560.1994.tb00278.x
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012). Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16(1), 103–119. https://doi.org/10.1517/14728222.2011.645805
Shen, J., Yang, J., Sang, L., Sun, R., Bai, W., Wang, C., Sun, Y., & Sun, J. (2021). PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Cancer Biology & Medicine, 19(8), 1211–1223.
Shi, Y., Paluch, B. E., Wang, X., & Jiang, X. (2012). PTEN at a glance. Journal of Cell Science, 125(20), 4687–4692. https://doi.org/10.1242/jcs.093765
Sinnberg, T., Makino, E., Krueger, M. A., Velic, A., Macek, B., Rothbauer, U., Groll, N., Pötz, O., Czemmel, S., Niessner, H., et al. (2016). A Nexus consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. eBioMedicine, 8, 132–149. https://doi.org/10.1016/j.ebiom.2016.04.037
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 487(7408), 500–504. https://doi.org/10.1038/nature11183
Tian, Y., & Guo, W. (2020). A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. Medical Science Monitor, 26, e920957.
Voldborg, B. R., Damstrup, L., Spang-Thomsen, M., & Poulsen, H. S. (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 8(12), 1197–1206. https://doi.org/10.1023/a:1008209720526
Wagenaar, T. R., Ma, L., Roscoe, B., Park, S. M., Bolon, D. N., & Green, M. R. (2014). Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Pigment Cell & Melanoma Research, 27(1), 124–133. https://doi.org/10.1111/pcmr.12171
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., Macconaill, L. E., Hahn, W. C., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology, 29(22), 3085–3096. https://doi.org/10.1200/jco.2010.33.2312
Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., Lopez-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., et al. (2015). BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research, 21(7), 1652–1664. https://doi.org/10.1158/1078-0432.Ccr-14-1554
Yan, C. H., Bai, W. Y., Zhang, Z. M., Shen, J. L., Wang, Y. J., & Sun, J. W. (2023). The roles and mechanism of STIM1 in tumorigenesis and metastasis. Yi Chuan, 45(5), 395–408.
Yilmaz, M., & GüvenMeşe, Ş. (2020). Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAF(V600E)-mutant metastatic melanoma. Journal of Oncology Pharmacy Practice, 26(7), 1754–1758. https://doi.org/10.1177/1078155220906011
Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer, 9(11), 798–809. https://doi.org/10.1038/nrc2734
Zhu, C., Wei, Y., & Wei, X. (2019). AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Molecular Cancer, 18(1), 153. https://doi.org/10.1186/s12943-019-1090-3
Zuo, Q., Liu, J., Huang, L., Qin, Y., Hawley, T., Seo, C., Merlino, G., & Yu, Y. (2018). AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene, 37(24), 3275–3289. https://doi.org/10.1038/s41388-018-0205-4
Acknowledgements
We thank Dr. Jing Li for the critical reading of the manuscript. This work was supported by the National Natural Science Foundation of China (82273460, 32260167), the Yunnan Applied Basic Research Projects (202101AV070002), a grant (Grant No. KLTIPT-2023-02) from Key Laboratory of Tumor Immunological Prevention and Treatment in Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University, Kunming and grants (Grant No. 2023Y0222) from Yunnan University.
Author information
Authors and Affiliations
Contributions
KG and JS were responsible for the study concept and design. KG, WB, ZZ, HX and RS drafted the manuscript. JS and JS revised and edited the manuscript. All authors contributed to this review and approved the submitted version.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Golub, K., Bai, W., Zhang, Z. et al. The mechanism and consequences of BRAF inhibitor resistance in melanoma. GENOME INSTAB. DIS. 4, 266–274 (2023). https://doi.org/10.1007/s42764-023-00105-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s42764-023-00105-5